Molecular Partners (MOLN) Competitors $5.28 -0.14 (-2.58%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrends MOLN vs. ADAP, ADVM, KOD, KPTI, TCRR, EOLS, RAPP, CRON, PLRX, and KURAShould you be buying Molecular Partners stock or one of its competitors? The main competitors of Molecular Partners include Adaptimmune Therapeutics (ADAP), Adverum Biotechnologies (ADVM), Kodiak Sciences (KOD), Karyopharm Therapeutics (KPTI), TCR2 Therapeutics (TCRR), Evolus (EOLS), Rapport Therapeutics (RAPP), Cronos Group (CRON), Pliant Therapeutics (PLRX), and Kura Oncology (KURA). These companies are all part of the "medical" sector. Molecular Partners vs. Adaptimmune Therapeutics Adverum Biotechnologies Kodiak Sciences Karyopharm Therapeutics TCR2 Therapeutics Evolus Rapport Therapeutics Cronos Group Pliant Therapeutics Kura Oncology Adaptimmune Therapeutics (NASDAQ:ADAP) and Molecular Partners (NASDAQ:MOLN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their community ranking, earnings, analyst recommendations, valuation, risk, media sentiment, dividends, institutional ownership and profitability. Does the media refer more to ADAP or MOLN? In the previous week, Adaptimmune Therapeutics had 11 more articles in the media than Molecular Partners. MarketBeat recorded 11 mentions for Adaptimmune Therapeutics and 0 mentions for Molecular Partners. Adaptimmune Therapeutics' average media sentiment score of 0.53 beat Molecular Partners' score of 0.00 indicating that Adaptimmune Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Adaptimmune Therapeutics Positive Molecular Partners Neutral Does the MarketBeat Community prefer ADAP or MOLN? Adaptimmune Therapeutics received 304 more outperform votes than Molecular Partners when rated by MarketBeat users. Likewise, 62.95% of users gave Adaptimmune Therapeutics an outperform vote while only 46.15% of users gave Molecular Partners an outperform vote. CompanyUnderperformOutperformAdaptimmune TherapeuticsOutperform Votes31662.95% Underperform Votes18637.05% Molecular PartnersOutperform Votes1246.15% Underperform Votes1453.85% Which has more volatility and risk, ADAP or MOLN? Adaptimmune Therapeutics has a beta of 2.26, suggesting that its stock price is 126% more volatile than the S&P 500. Comparatively, Molecular Partners has a beta of 0.98, suggesting that its stock price is 2% less volatile than the S&P 500. Which has stronger valuation & earnings, ADAP or MOLN? Molecular Partners has lower revenue, but higher earnings than Adaptimmune Therapeutics. Adaptimmune Therapeutics is trading at a lower price-to-earnings ratio than Molecular Partners, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdaptimmune Therapeutics$175.04M0.97-$113.87M-$0.22-3.01Molecular Partners$7.84M27.17-$69.04M-$2.15-2.46 Do insiders and institutionals believe in ADAP or MOLN? 31.4% of Adaptimmune Therapeutics shares are held by institutional investors. Comparatively, 26.6% of Molecular Partners shares are held by institutional investors. 12.4% of Adaptimmune Therapeutics shares are held by insiders. Comparatively, 5.9% of Molecular Partners shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is ADAP or MOLN more profitable? Adaptimmune Therapeutics has a net margin of -25.43% compared to Molecular Partners' net margin of -1,043.01%. Molecular Partners' return on equity of -39.31% beat Adaptimmune Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Adaptimmune Therapeutics-25.43% -74.15% -15.09% Molecular Partners -1,043.01%-39.31%-35.46% Do analysts prefer ADAP or MOLN? Adaptimmune Therapeutics presently has a consensus price target of $3.16, suggesting a potential upside of 378.01%. Molecular Partners has a consensus price target of $4.50, suggesting a potential downside of 14.77%. Given Adaptimmune Therapeutics' higher probable upside, analysts plainly believe Adaptimmune Therapeutics is more favorable than Molecular Partners.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adaptimmune Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Molecular Partners 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 3.00 SummaryAdaptimmune Therapeutics beats Molecular Partners on 13 of the 18 factors compared between the two stocks. Ad Weiss Ratings“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.Learn these 4 simple steps and protect your savings before it’s too late. Get Molecular Partners News Delivered to You Automatically Sign up to receive the latest news and ratings for MOLN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MOLN vs. The Competition Export to ExcelMetricMolecular PartnersBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$213.00M$3.04B$5.38B$8.84BDividend YieldN/A1.91%5.13%4.09%P/E Ratio-2.4644.06102.4617.58Price / Sales27.17392.921,234.85158.43Price / CashN/A169.3840.4736.33Price / Book1.334.597.096.50Net Income-$69.04M-$41.63M$119.65M$226.22M7 Day Performance-0.94%2.61%2.06%3.76%1 Month Performance-6.88%-2.47%-2.46%4.63%1 Year Performance21.66%28.24%33.95%29.20% Molecular Partners Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MOLNMolecular Partners0.2478 of 5 stars$5.28-2.6%$4.50-14.8%+21.7%$213.00M$7.84M-2.46180Gap UpADAPAdaptimmune Therapeutics2.122 of 5 stars$0.63-4.5%$3.16+399.5%+47.3%$162.00M$60.28M-2.88449ADVMAdverum Biotechnologies4.1174 of 5 stars$5.80-6.0%$27.83+379.9%-28.1%$128.35M$1M-0.97190Analyst ForecastHigh Trading VolumeKODKodiak Sciences2.979 of 5 stars$5.90+1.9%$3.50-40.7%+157.9%$310.46MN/A-1.6290KPTIKaryopharm Therapeutics3.9437 of 5 stars$0.77-1.3%$5.00+550.2%+18.9%$97.12M$148.44M-0.67380Analyst DowngradeNews CoverageTCRRTCR2 TherapeuticsN/A$1.48-5.7%N/A+0.0%$58.11MN/A-0.35137High Trading VolumeEOLSEvolus4.0382 of 5 stars$13.09+3.6%$23.00+75.8%+34.0%$828.59M$202.09M-14.36170Positive NewsRAPPRapport Therapeutics1.7408 of 5 stars$22.52+1.5%$35.00+55.4%N/A$823.78MN/A0.00N/APositive NewsCRONCronos Group1.8238 of 5 stars$2.05+2.0%$3.00+46.3%+4.0%$783.72M$87.24M-15.46356PLRXPliant Therapeutics3.4996 of 5 stars$12.85+0.9%$40.57+215.7%-6.8%$781.92M$1.58M-3.8590KURAKura Oncology4.0734 of 5 stars$10.00-37.1%$29.43+194.3%+15.0%$777.68MN/A-4.45142Analyst ForecastNews CoverageGap UpHigh Trading Volume Related Companies and Tools Related Companies Adaptimmune Therapeutics Competitors Adverum Biotechnologies Competitors Kodiak Sciences Competitors Karyopharm Therapeutics Competitors TCR2 Therapeutics Competitors Evolus Competitors Rapport Therapeutics Competitors Cronos Group Competitors Pliant Therapeutics Competitors Kura Oncology Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MOLN) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Molecular Partners AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Molecular Partners With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
